BD Reports 4th Quarter and Full Year Fiscal 2022 Financial Results.

FRANKLIN LAKES, N.J: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fourth quarter and full year of fiscal 2022, which ended September 30, 2022.

"Fiscal 2022 was another outstanding year with impactful results that confirm the effectiveness of our BD 2025 strategy," said Tom Polen, chairman, CEO and president of BD. "We delivered reliable, consistent performance that reflects our team's unwavering commitment to our purpose and the execution of our growth plan - while navigating the challenging macro environment all companies are facing. Looking forward, our strong performance and momentum increases our confidence to continue to create substantial, sustained value for all stakeholders."

Recent Business Highlights

BD continues to advance its innovation-driven growth strategy, tuck-in M&A, and ESG initiatives.

Launched BD(r) Research Cloud in the US. State-of-the-art software solution streamlines research flow cytometry workflow through integrated ecosystem that enables customers to design, run and analyze experiments.

Launched BD Effivax. Next-generation glass prefillable syringe sets new standard in performance for vaccines.

Announced agreement with Biocorp to bring connectivity and traceability to self-administered injectable drug therapies like biologics, addressing an unmet need and furthering BD's commitment to smart, connected care, enabling care to transition to alternate settings and improving chronic disease outcomes.

Named to Forbes' 2022 list of the World's Best Employers.

Basis of Presentation-- Continuing Operations

On April 1, 2022, the Company completed the spin-off of its Diabetes Care business as a separate publicly traded company named Embecta Corp. ("Embecta"). The historical results of the Diabetes Care business that was contributed to Embecta in the spin-off are now accounted for as discontinued operations. Financial information presented in this release reflects BD's results on a continuing operations basis, which excludes Embecta. Prior periods have been recast to conform to this presentation.

Fourth Quarter Fiscal 2022 Operating Results

Three Months Ended September 30,

Change

Foreign Currency

Neutral Change1

(Millions of dollars, except per share amounts)

2022

2021

Revenues

$ 4,761

$ 4,849

(1.8) %

2.3 %

Base Revenues1

$ 4,724

$ 4,533

4.2 %

8.6 %

Base Organic Revenue Growth1

2.4 %

6.8 %

Reported Diluted Earnings per Share

$ 0.92

$ 0.46

100.0 %

137.0 %

Adjusted Diluted Earnings per Share1

$ 2.75

$ 2.15

27.9 %

36.3 %

1Represents a non-GAAP...